A study to find out how well Rilvegostomig works and how safe it is compared to Pembrolizumab as a first-line treatment for adults with metastatic non-small cell lung cancer (NSCLC) with high PD-L1 levels
Summary description of the study
The study drug Rilvegostomig is intended to help the immune system kill cancer cells by blocking 2 proteins on immune cells: PD-L1 and another protein called TIGIT. Researchers believe that Rilvegostomig may work better than Pembrolizumab as a first-line treatment for adults with metastatic NSCLC with high PD-L1 levels. In this study, researchers want to find out how well Rilvegostomig works and how safe it is compared to Pembrolizumab. This is a randomized phase 3 double-blind study. Randomized means that a computer program randomly assigns the treatment each participant receives (either Rilvegostomig or Pembrolizumab) (like flipping a coin). Double-blind means that none of the participants, researchers, study doctors, or other study staff know which treatment each participant is receiving. Participants will continue to receive the study treatment unless their cancer worsens, they have significant medical problems, or they leave the study for another reason.
(BASEC)
Intervention under investigation
Participants will receive treatment (either Rilvegostomig or Pembrolizumab) every 3 weeks from trained staff through a needle into the vein (intravenously) until their cancer worsens, they have significant medical problems, or they leave the study for another reason. To monitor the health of participants during the study, doctors will do the following: ► Blood and urine tests ► Physical examinations ► Monitoring of vital signs (heart rate, respiratory rate, blood pressure, and body temperature) ► CT and/or MRI scans ► Testing heart function using an electrocardiogram (ECG) and other tests ► Inquiring about participants' medications and any medical problems.
(BASEC)
Disease under investigation
Metastatic non-small cell lung cancer (NSCLC)
(BASEC)
Documented metastatic non-small cell lung cancer (NSCLC) stage IV with high PD-L1 levels, with no prospect of curative treatment. Minimum life expectancy of 12 weeks. (BASEC)
Exclusion criteria
At the discretion of the investigator, any severe or uncontrolled systemic diseases. History of organ transplantation. Active or previously documented autoimmune or inflammatory diseases requiring chronic treatment with steroids or other immunosuppressive agents. (BASEC)
Trial sites
Lausanne
(BASEC)
Sponsor
AstraZeneca AB, Sweden Fortrea Switzerland AG, Zürich
(BASEC)
Contact
Contact Person Switzerland
Dr. Hasna Bouchabb
+41 (0)79 556 84 37
hasna.bouchaab@clutterchuv.chCHUV | Centre hospitalier universitaire vaudois, rue du bugnon 46, 1011 Lausanne
(BASEC)
Scientific Information
not available
Name of the authorising ethics committee (for multicentre studies, only the lead committee)
Ethics Committee Vaud
(BASEC)
Date of authorisation
28.08.2025
(BASEC)
ICTRP Trial ID
not available
Official title (approved by ethics committee)
TITLE PAGE A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer (ARTEMIDE-Lung04) (BASEC)
Academic title
not available
Public title
not available
Disease under investigation
not available
Intervention under investigation
not available
Type of trial
not available
Trial design
not available
Inclusion/Exclusion criteria
not available
not available
Primary and secondary end points
not available
not available
Registration date
not available
Incorporation of the first participant
not available
Secondary sponsors
not available
Additional contacts
not available
Secondary trial IDs
not available
Results-Individual Participant Data (IPD)
not available
Further information on the trial
not available
Results of the trial
Results summary
not available
Link to the results in the primary register
not available